SAN DIEGO, Sept. 6 /PRNewswire-FirstCall/ -- MicroIslet, Inc. (Amex: MII - News), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, today announced that will present an update on the Company’s islet transplantation development strategy and progress at the Oppenheimer & Co. Second Annual Diabetes Conference. The conference will be held at the Jolly Hotel, Madison Towers, New York City.
MicroIslet’s presentation will take place at 11:30 a.m. Eastern time on Thursday, September 21, 2006, and will be webcast live at: http://www.internetvideochannel.com/oppenheimer/diabetes.asp.
An archived version of the webcast will be available until October 22.
“We are pleased to update the Oppenheimer conference attendees on the progress we are making toward an improved diabetes treatment paradigm,” commented James R. Gavin III, M.D., Ph.D., President and Chief Executive Officer of MicroIslet. “As we recently announced, we have achieved long-term survival of transplanted insulin-producing islets in ongoing studies in primates, and the primate subjects have experienced improved glycemic control for at least six months. Our method for islet microencapsulation eliminates the need for chronic immunosuppression to prevent rejection of the transplanted tissues. The transplantation site in the peritoneum allows a minimally invasive procedure, and we have secured access to a sufficient supply of islet tissues through our exclusive, long-term islet supply agreement with the Mayo Foundation for Medical Education and Research.”
About MicroIslet
MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. MicroIslet’s patented islet transplantation technology, exclusively licensed from Duke University, includes methods for isolating, culturing, cryopreservation, and immuno-protection (microencapsulation) of islet cells. MicroIslet is working to develop and commercialize a first product, called MicroIslet-P(TM), a microencapsulated porcine islet cell suspension that will be used for transplantation in patients with insulin-dependent diabetes. Additional information about MicroIslet can be found at www.microislet.com.
Except for the historical information contained herein, the matters set forth in this press release, including the implication and interpretation of preliminary data, the expectation of development of new therapeutic products and the impact of MicroIslet’s products on diabetes patients, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including MicroIslet’s ability to continue as a going concern, the risks and uncertainties inherent in medical treatment discovery, development and commercialization, the risks and uncertainties associated with MicroIslet’s early stage xenotransplantation technologies, the risks and uncertainties of governmental approvals and regulation, dependence on the Mayo Foundation for Medical Education and Research as a sole source supplier of animal parts for pre-clinical and clinical studies, MicroIslet’s need to raise substantial additional capital to proceed through human clinical trials and bring any product to market, the risks that MicroIslet’s competitors will develop or market technologies or products that are more effective or commercially attractive than MicroIslet’s products, and other risks detailed from time to time in MicroIslet’s most recent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. MicroIslet disclaims any intent or obligation to update these forward-looking statements.
For more information, please visit our Web site at www.microislet.com.
For further information, contact:
Kevin A. Hainley, MicroIslet Inc. 858-657-0287, info@microislet.com
Sean Collins, Senior Partner CCG Investor Relations & Strategic Communications 310-231-8600 ext. 202
ISIN US59507Q1067
-------------------------------------------------------------------------------- Source: MicroIslet, Inc.
